1269 related articles for article (PubMed ID: 16632482)
1. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.
Stasi R; Stipa E; Del Poeta G; Amadori S; Newland AC; Provan D
Rheumatology (Oxford); 2006 Nov; 45(11):1432-6. PubMed ID: 16632482
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab for refractory head and neck Wegener's granulomatosis: a cohort study.
Martinez Del Pero M; Chaudhry A; Jones RB; Sivasothy P; Jani P; Jayne D
Clin Otolaryngol; 2009 Aug; 34(4):328-35. PubMed ID: 19673980
[TBL] [Abstract][Full Text] [Related]
3. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients.
Lovric S; Erdbruegger U; Kümpers P; Woywodt A; Koenecke C; Wedemeyer H; Haller H; Haubitz M
Nephrol Dial Transplant; 2009 Jan; 24(1):179-85. PubMed ID: 18685144
[TBL] [Abstract][Full Text] [Related]
4. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.
Keogh KA; Wylam ME; Stone JH; Specks U
Arthritis Rheum; 2005 Jan; 52(1):262-8. PubMed ID: 15641078
[TBL] [Abstract][Full Text] [Related]
5. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
[TBL] [Abstract][Full Text] [Related]
6. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab.
Eriksson P
J Intern Med; 2005 Jun; 257(6):540-8. PubMed ID: 15910558
[TBL] [Abstract][Full Text] [Related]
7. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
8. Clinical and pathological characteristics and outcomes of Chinese patients with primary anti-neutrophil cytoplasmic antibodies-associated systemic vasculitis with immune complex deposition in kidney.
Yu F; Chen M; Wang SX; Zou WZ; Zhao MH; Wang HY
Nephrology (Carlton); 2007 Feb; 12(1):74-80. PubMed ID: 17295665
[TBL] [Abstract][Full Text] [Related]
9. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
Brijker F; Magee CC; Tervaert JW; O'Neill S; Walshe JJ
Clin Nephrol; 1999 Dec; 52(6):344-51. PubMed ID: 10604641
[TBL] [Abstract][Full Text] [Related]
10. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.
Gellrich S; Muche JM; Wilks A; Jasch KC; Voit C; Fischer T; Audring H; Sterry W
Br J Dermatol; 2005 Jul; 153(1):167-73. PubMed ID: 16029344
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis.
Gao Y; Chen M; Ye H; Yu F; Guo XH; Zhao MH
Rheumatology (Oxford); 2008 Oct; 47(10):1515-20. PubMed ID: 18676500
[TBL] [Abstract][Full Text] [Related]
12. Off-trial evaluation of the B cell-targeting treatment in the refractory cases of antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: long-term follow-up from a single centre.
Pullerits R; Ljevak M; Vikgren J; Bokarewa M
Scand J Immunol; 2012 Oct; 76(4):411-20. PubMed ID: 22823472
[TBL] [Abstract][Full Text] [Related]
13. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
14. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
15. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
16. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis.
Slot MC; Tervaert JW; Boomsma MM; Stegeman CA
Arthritis Rheum; 2004 Apr; 51(2):269-73. PubMed ID: 15077271
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of antineutrophil cytoplasmic antibodies in small-vessel vasculitis.
Lurati-Ruiz F; Spertini F
J Rheumatol; 2005 Nov; 32(11):2167-72. PubMed ID: 16265696
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations.
Seo P; Specks U; Keogh KA
J Rheumatol; 2008 Oct; 35(10):2017-23. PubMed ID: 18688911
[TBL] [Abstract][Full Text] [Related]
19. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
[TBL] [Abstract][Full Text] [Related]
20. Rituximab is effective in the treatment of refractory ophthalmic Wegener's granulomatosis.
Taylor SR; Salama AD; Joshi L; Pusey CD; Lightman SL
Arthritis Rheum; 2009 May; 60(5):1540-7. PubMed ID: 19404964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]